Back to matchesWe found a matchYour institution may have access to this item. Find your institution then sign in to continue.TitleAmivantamab vs Mobocertinib in Exon 20 NSCLC.AuthorsSpira, Alexander I.; Bestvina, Christine; Sabari, Joshua K.; Das, Millie; Misako NagasakaSubjectsLUNG cancer; DRUG efficacy; MONOCLONAL antibodies; ANTINEOPLASTIC agents; TREATMENT effectiveness; CANCER patients; DECISION making in clinical medicine; DRUG development; PATIENT safety; DRUG toxicity; PHARMACODYNAMICSPublicationOncology (08909091), 2023, Vol 37, Issue 8, p340ISSN0890-9091Publication typeArticle